Zimmer Biomet (NYSE:ZBH – Get Free Report) had its price objective boosted by equities researchers at Stifel Nicolaus from $125.00 to $140.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus‘s price target suggests a potential upside of 35.68% from the company’s current price.
A number of other research firms have also weighed in on ZBH. Argus restated a “buy” rating and set a $125.00 target price on shares of Zimmer Biomet in a report on Thursday, October 22nd. JPMorgan Chase & Co. increased their target price on Zimmer Biomet from $117.00 to $120.00 and gave the company a “neutral” rating in a research report on Thursday, November 5th. Jefferies Financial Group reiterated a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Wednesday, November 4th. Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Finally, Citigroup upped their price objective on Zimmer Biomet from $99.00 to $117.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. Seven analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $113.53.
Read Our Latest Stock Report on ZBH
Zimmer Biomet Price Performance
Shares of ZBH opened at $103.18 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46. The company has a 50 day moving average price of $95.76 and a 200-day moving average price of $92.57. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $112.54. The stock has a market capitalization of $19.53 billion, a PE ratio of 26.12, a PEG ratio of 2.42 and a beta of 0.50.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. Zimmer Biomet’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. Equities analysts predict that Zimmer Biomet will post 8.56 earnings per share for the current fiscal year.
Insider Activity at Zimmer Biomet
In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.
Hedge Funds Weigh In On Zimmer Biomet
A number of large investors have recently made changes to their positions in the business. Tacita Capital Inc purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $26,000. Ancora Advisors LLC acquired a new stake in shares of Zimmer Biomet in the 2nd quarter worth $29,000. Elevation Wealth Partners LLC grew its stake in Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in Zimmer Biomet during the 1st quarter worth $44,000. Finally, United Southern Bank Trust Department purchased a new position in Zimmer Biomet during the 3rd quarter worth $47,000. 88.89% of the stock is owned by institutional investors and hedge funds.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
See Also
- Five stocks we like better than Zimmer Biomet
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
